Table 1. Characteristics of the BASE-II participants included in the present study.
| Men (n = 270) | Women (n = 336) | p-value | |
|---|---|---|---|
| Age [years] | 68 (60–80) | 68 (61–84) | 0.385 |
| BMI [kg/m2] | 27.1±3.5 | 26.5±4.8 | 0.077 |
| FEV1 [ml] | 2985±592 | 2134±441 | < 0.001 |
| FVC [ml] | 4090±681 | 2861±513 | < 0.001 |
| FEV1/FVC [%] | 74.3 (69.5–78.1) | 75.4 (71.0–78.9) | 0.040 |
| Smoking status [n;%] | |||
| Current | 33 (12) | 35 (11) | |
| Former | 146 (54) | 107 (32) | < 0.001 |
| Never | 93 (34) | 192 (58) | |
| Regular alcohol intake [n;%] | 245 (90) | 295 (88) | 0.515 |
| Lp(a) [mg/l] | 100 (40–343) | 143 (70–440) | 0.012 |
| Total cholesterol [mg/dl] | 203±36 | 227±37 | < 0.001 |
| HDL-cholesterol [mg/dl] | 56±14 | 71±17 | < 0.001 |
| LDL-cholesterol [mg/dl] | 123±33 | 136±34 | < 0.001 |
| Triglycerides [mg/dl] | 106 (77–143) | 89 (71–119) | < 0.001 |
| Apo A1 [g/l] | 1.79±0.28 | 1.54±0.25 | < 0.001 |
| Apo B [g/l] | 1.01±0.23 | 1.00±0.25 | 0.753 |
| HOMA-IR | 2.1±1.7 | 2.7±3.4 | < 0.001 |
| Antihyperlipidemic treatment [n;%] | 53 (20) | 46 (14) | 0.097 |
| Self-reported physical inactivity [n;%] | 20 (7.5) | 26 (7.8) | 1.000 |
| T2D [n;%] | 41 (17) | 38 (12) | 0.087 |
| TSH [mU/l] | 1.75 (1.24–2.43) | 1.85 (1.33–2.72) | 0.258 |
| GFR [ml/min] | 84.6±17.2 | 75.6±18.0 | < 0.001 |
| CRP [mg/dl] | 1.1 (0.6–2.1) | 1.2 (0.6–2.3) | 0.376 |
| IL-6 [pg/ml] # | 1.4 (0.8–2.2) | 1.1 (0.8–1.6) | 0.442 |
| IL-10 [pg/ml]# | 0.32 (0.23–0.54) | 0.32 (0.17–0.43) | 0.628 |
Results are shown as mean ±SD,median (range) or meas (interquartile range) for variables with a skewed distribution
# IL-6 and IL-10 were determined for a sub-sample of 91 participants